الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 135 |  |  |
| | | from | 135 | | |
Abstract
Diabetes mellitus (DM) has been recognized as a key factor contributing to the development of solid organ malignancies. The strongest associations to type-2 DM are those of the liver, pancreas and breast .In Egypt, hepatocellular carcinoma (HCC) is the second most common cancer in men and the 6th most common cancers in women.
Aim of the work:
The current study was designed to assess and compare the effect of bromocriptine mesylate and l-arginine on hepatic carcinogenesis to some currently used anti-diabetic drugs. The former was FDA approved for treatment of type-2 DM since 2009, while the latter improved diabetic control in clinical trials. The hepatic pre-neo-plastic changes were initiated by a carcinogen, diethyl nitrosamine (DENA) and promoted by type-2 DM in rats.
Methodology:
Animals:
100 male albino rats were divided into 2 groups (GI: 40 rats and GII: 60 rats) each subgroup of 10 rats in a 10 weeks study.
Group-I (untreated group) included:(1) Control group, (2) DENA group that received DENA 125 mg / kg intra-peritoneal (IP) at the 2nd week, (3) DM group in which type -2 DM was induced by 5 weeks high fat diet and STZ 50mg /kg IP at the beginning of the 5th week and (4) Combined DENA injection and type-2 DM induction group. Diabetic rats with blood sugar over 250 mg /dl were those included in the study.